

P2Y₂R has a significant correlation with Notch-4 in patients with breast cancer

DONG CHUL KIM^{1*}, HANA JIN^{2*}, JONG SIL LEE¹, EUNA SON³, GYEONG WON LEE⁴ and HYE JUNG KIM²

Departments of ¹Pathology and ²Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, Jinju, South Gyeongsang 52727; ³Division of Life Science, College of Natural Sciences, Gyeongsang National University, Jinju, South Gyeongsang 52828; ⁴Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Gyeongsang National University Hospital, Gyeongsang National University, Jinju, South Gyeongsang 52727, Republic of Korea

Received January 9, 2020; Accepted April 8, 2020

DOI: 10.3892/ol.2020.11630

Abstract. Our previous study found that highly metastatic breast cancer cells, such as MDA-MB-231 cells, release higher levels of ATP and exhibit greater P2Y₂ receptor (P2Y₂R) activity than lowly metastatic breast cancer cells, and that P2Y₂R activation mediated by ATP plays a significant role in tumor progression and metastasis. In addition, we reported that radiotherapy-resistant (RT-R) breast cancer cells promote invasion and tumor growth through the activation of P2Y₂R by ATP released from RT-R-breast cancer cells than breast cancer cells. Moreover, increased numbers of cancer stem cells (CSCs) were observed among the RT-R-breast cancer cell population. Therefore, in this study, we investigated the expression level of five CSC markers (CD24, CD44, Oct3/4, Notch-4 and ALDH1A1) as well as P2Y₂R in the tumor tissues of patients with breast cancer and determined which CSC

marker correlates with P2Y₂R in breast cancer. According to the immunohistochemical analysis, CD44, Oct3/4 and Notch-4 but not ALDH1A1 were significantly expressed in the tumor tissues (n=180) compared with the normal epithelial tissues (n=20) of patients with breast cancer. It was demonstrated that P2Y₂R expression was increased in tumor tissues of patients with breast cancer compared with normal epithelial tissue. Notably, it was identified that P2Y₂R expression has a significant correlation with only the CSC marker Notch-4 in patients with breast cancer. The results of this study suggested for the first time to the best of our knowledge that Notch-4 has a notable correlation with P2Y₂R, which has important roles in tumor progression and metastasis.

Introduction

Breast cancer is one of the leading causes of cancer-related death in women (1). Although most breast cancer patients respond to traditional treatments, such as tumor removal surgery, chemotherapy and radiation, the disease becomes difficult to treat and causes death with recurrence and metastasis to distant organs. Metastasis is the process by which cancer cells migrate from a site of origin and develop in neighboring locations, and rather than the primary tumor itself, metastasis is responsible for the majority of cancer-related deaths (2-4). Recently, it has been proposed that cancer stem cells (CSCs) exist in tumors and contribute to tumorigenesis, aggressiveness, metastasis to distant organs, resistance to different types of anticancer therapeutic strategies, including radiation therapy and chemotherapy, and disease recurrence. CSCs are known to be able to self-renew and regenerate heterogeneous populations that consist of tumor cells after treatment (5). Some or all of these cells, which are present in a tumor in specific microenvironments or niches, render tumor cells more resistant to radiation therapy and chemotherapy, ultimately leading to tumor regrowth and distant metastasis (6-10).

The P2Y₂ receptor (P2Y₂R) belongs to the family of G protein-coupled P2Y receptors and is most consistently expressed (or overexpressed) by tumor cells; P2Y₂R mediates various responses, including proliferation, in many

Correspondence to: Professor Hye Jung Kim, Department of Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, 816 Bungil 15, Jinjudaero, Jinju, South Gyeongsang 52727, Republic of Korea
E-mail: hyejungkim@gnu.ac.kr

Professor Gyeong Won Lee, Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Gyeongsang National University Hospital, Gyeongsang National University, 816 Bungil 15, Jinjudaero, Jinju, South Gyeongsang 52727, Republic of Korea
E-mail: brighttree@naver.com

*Contributed equally

Abbreviations: ALDH, aldehyde dehydrogenase; AM, adhesion molecule; CSC, cancer stem cell; EC, endothelial cell; EMT, epithelial mesenchymal transition; HIF, hypoxia-inducible factor; LOX, lysyl oxidase; MMP, matrix metalloproteinase; TNBC, triple-negative breast cancer

Key words: breast cancer, CSC markers, CD44, Notch-4, Oct3/4, P2Y₂ receptor

tumors (11-14) upon activation by ATP, which is released in the tumor microenvironment (15). In our previous study, we reported that MDA-MB-231 breast cancer cells, which show highly metastatic properties, release higher levels of ATP and show greater P2Y₂R activity than lowly metastatic breast cancer cells, such as MCF-7 cells, and that P2Y₂R activation by ATP plays an important role in tumor progression and metastasis by regulating various responses in tumor cells and by modulating crosstalk between cancer cells and endothelial cells (ECs) (16). In addition, ATP-mediated activation of P2Y₂R in monocytes induces their recruitment toward a tumor and promotes inflammatory conditions around primary tumors by secreting matrix metalloproteinase. In breast cancer cells, P2Y₂R activation by ATP induces hypoxia-inducible factor (HIF)-1 α expression, lysyl oxidase (LOX) secretion, and collagen crosslinking, which results in premetastatic niche formation (17). Moreover, we found that radiotherapy-resistant (RT-R) breast cancer cells, particularly RT-R-MDA-MB-231 cells derived from the highly metastatic breast cancer cell line MDA-MB-231, release high levels of ATP, promoting invasion and tumor growth through activation of P2Y₂R (18). Furthermore, more CSCs developed among RT-R-MDA-MB-231 cells, contributing to the acquisition of tolerance to other anticancer therapies in addition to radiation therapy (19). Thus, we hypothesized that P2Y₂R may have a relationship with CSCs in breast cancer, and we aimed to evaluate CSC marker expression in human breast cancer and to determine their relationship with P2Y₂R in human breast cancer. In this study, we investigated the expression level of 5 CSC markers (CD24, CD44, Oct3/4, Notch-4 and ALDH1A1) and P2Y₂R in human breast cancer patients and examined the correlation of CSC markers with P2Y₂R.

Materials and methods

Case selection. This retrospective study was approved by the Institutional Review Board of Gyeongsang National University Hospital with a waiver of informed consent (GNUH-2018-05-010). Specimens from 180 breast cancer patients who underwent surgery with wide excision or mastectomy between January 2010 and December 2012 at Gyeongsang National University Hospital, Jinju, Korea, were selected. For each sample, formalin-fixed, paraffin-embedded and hematoxylin and eosin-stained sections were prepared on glass slides and assessed by two pathologists. Data from electronic medical records, including sex, age, menstrual status, tumor size, lymph node status, distant metastasis, and tumor stage, were reviewed. Cancer stages were determined according to the eighth edition of the American Joint Committee on Cancer (AJCC). Histological type and grade were determined per the fifth edition of the World Health Organization (WHO) classification. As shown in Table I, all patients except one were female (179), with a mean age of 51.5 years old (range, 25~81). Patients <50 years old accounted for 50.6; 56.1% of the patients were premenopausal; 91.7% of patients had a tumor diameter classified as T1/T2, whereas 8.3% had a tumor diameter classified as T3/T4; 85.0% had an N0/N1 lymph node grade, whereas 15.0% had an N2/N3 lymph node grade; 80.6% were at stage I/II, whereas 19.4% were at stage III/IV. Cases were divided into three groups according to ER, PR and HER-2 expression: i) triple-negative breast cancer (TNBC), ER, PR

and HER-2 negative (n=20; 11.1%); ii) HER-2-breast cancer, ER and PR negative (n=7; 3.9%); iii) luminal breast cancer, ER and/or PR positive, HER-2 negative or positive (n=153; 85.0%). The criteria for ER- and PR-positive staining was a score >3 by the Allred scoring system. HER-2 was considered positive if >10% of the cancer cells presented with strong and complete brown cell membrane staining (Table II).

Tissue microarray and immunohistochemistry. Representative hematoxylin and eosin-stained sections on glass slides containing prominent intratumoral regions from 180 breast cancer patient specimens were chosen. Two 2-mm tissue cores were obtained from each representative paraffin block and transferred to recipient tissue microarray (TMA) blocks, and immunohistochemical staining was performed on the TMA blocks using anti-P2Y₂R polyclonal (1:200 dilution, #PA1-46150; Thermo Fisher Scientific, Inc.), anti-CD24 monoclonal (1:100 dilution, #ab31622; Abcam), anti-CD44 monoclonal (1:100 dilution, #ab51037; Abcam), anti-Oct3/4 polyclonal (1:100 dilution, #ab18976; Abcam), anti-Notch-4 polyclonal (1:50 dilution, #ab199295; Abcam), and anti-ALDH1A1 monoclonal (1:100 dilution, #ab52492; Abcam) primary antibodies.

Evaluation of immunohistochemistry. CD24 and CD44 were interpreted as positive when staining in the cell membranes was observed in at least 10% of the cells. ALDH1A1 was interpreted as positive when staining in the cytoplasm was observed in at least 10% of the cells. Cytoplasmic expression of Oct3/4 was detected and classified into two groups: Low expression (0~50% cells) or high expression (51~100% cells). Membrane and nuclear expression of Notch-4 was recorded. A semi-quantitative scoring system was used, evaluating both the staining intensity (0, no stain; 1+, weak stain; 2+, moderate stain; 3+, strong stain) and percentage of stained cells (0, <5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, >75%). Scores for staining intensity and the percentage of positive cells were then multiplied to generate the immunoreactivity score (IS) for each case. All cases were sorted into two groups according to IS. High expression of Notch-4 was defined as detectable immunoreactivity in the cytoplasm and nucleus with IS \geq 4. Only nuclear expression of P2Y₂R was recorded, given a score from 0 to 12 according to the intensity (0, 1+, 2+, 3+) and percentage of positive tumor cells (0=all negative, 1+=0~10%, 2+=11~50%, 3+=51~80% and 4+=more than 81% of cells).

Statistical analysis. All statistics were analyzed using GraphPad Prism7 software (GraphPad Software, Inc.). One-way ANOVA followed by Newman-Keuls post hoc test was carried out to compare different groups. Data are presented as the mean \pm SEM. Coefficients of correlation (r) were determined by the Pearson correlation method. P<0.05 was considered to indicate a statistically significant difference. Correlation analyses were performed using the chi-square test and Fisher's exact test. SPSS version 25.0 (IBM Corp.) was used for the analysis.

Results

CD44, Oct3/4 and Notch-4 CSC markers are significantly expressed in the tumor tissue of breast cancer patients. First,

Table I. Association between cancer stem cell markers and clinicopathological characteristics in patients with breast cancer.

Clinicopathological characteristics	Total patients: 180 (%)	CD24 (%)			CD44 (%)			Oct3/4 (%)			Notch-4 (%)			ALDH1A1 (%)		
		Negative	Positive	P-value	Negative	Positive	P-value	Low	High	P-value	Low	High	P-value	Negative	Positive	P-value
Age, years				0.6504			0.2627			0.3424			0.4559			0.6187
<50	91 (50.6)	55 (60.4)	36 (39.6)		25 (27.5)	66 (72.5)		20 (22.0)	71 (78.0)		42 (46.1)	49 (53.9)		90 (99.0)	1 (1.0)	
≥50	89 (49.4)	50 (56.2)	39 (43.8)		32 (36.0)	57 (64.0)		14 (15.7)	75 (84.3)		36 (40.4)	53 (59.6)		87 (97.7)	2 (2.3)	
Menstrual status				0.1268			0.075			0.4451			0.8802			0.2582
Premenopausal	101 (56.1)	54 (53.5)	47 (46.5)		38 (37.6)	63 (62.4)		17 (16.8)	84 (83.2)		44 (43.6)	57 (56.4)		98 (97.0)	3 (3.0)	
Postmenopausal	78 (43.3)	51 (65.4)	27 (34.6)		19 (24.4)	59 (75.6)		17 (21.8)	61 (78.2)		33 (42.3)	45 (57.7)		78 (100.0)	0 (0.0)	
None (male)	1 (0.6)	1 (100.0)	0 (0.0)		0 (0.0)	1 (100.0)		0 (0.0)	1 (100.0)		1 (100.0)	0 (0.0)		1 (100.0)	0 (0.0)	
ER status				0.0812			0.5931			0.8332			<0.0001			0.1871
Negative	50 (27.8)	24 (48.0)	26 (52.0)		14 (28.0)	36 (72.0)		10 (20.0)	40 (80.0)		37 (74.0)	13 (26.0)		48 (96.0)	2 (4.0)	
Positive	130 (72.2)	81 (62.3)	49 (37.7)		43 (33.1)	87 (66.9)		24 (18.5)	106 (81.5)		41 (31.5)	89 (68.5)		129 (99.2)	1 (0.8)	
PR status				0.5021			0.8587			0.141			0.0185			
Negative	50 (27.8)	27 (54.0)	23 (46.0)		15 (30.0)	35 (70.0)		13 (26.0)	37 (74.0)		29 (58.0)	21 (42.0)		49 (98.0)	1 (2.0)	
Positive	130 (72.2)	78 (60.0)	52 (40.0)		42 (32.3)	88 (67.7)		21 (16.2)	109 (83.8)		49 (37.7)	81 (62.3)		128 (98.5)	2 (1.5)	
HER-2 status																
Negative	151 (83.9)	91 (60.3)	60 (39.7)	0.3039	45 (29.8)	106 (70.2)	0.2757	29 (19.2)	122 (80.8)	1	61 (40.4)	90 (59.6)	0.1006	148 (98.0)	3 (2.0)	
Positive	29 (16.1)	14 (48.3)	15 (51.7)		12 (41.4)	17 (58.6)		5 (17.2)	24 (82.8)		17 (58.6)	12 (41.4)		29 (100.0)	0 (0.0)	
Tumor size																
T1/T2	165 (91.7)	98 (59.4)	67 (40.6)	0.4152	55 (33.3)	110 (66.7)	0.15	30 (18.2)	135 (81.8)	0.054	69 (41.8)	96 (58.2)	0.1861	162 (98.2)	3 (1.8)	
T3/T4	15 (8.3)	7 (46.7)	8 (53.3)		2 (13.3)	13 (86.7)		4 (26.7)	11 (73.3)		9 (60.0)	6 (40.0)		15 (100.0)	0 (0.0)	
Lymph node involvement																
N0/N1	153 (85.0)	88 (57.5)	65 (42.5)	0.6751	45 (29.4)	108 (70.6)	0.1768	29 (18.9)	124 (81.1)	1	63 (41.2)	90 (58.8)	0.207	150 (98.0)	3 (2.0)	
N2/N3	27 (15.0)	17 (63.0)	10 (37.0)		12 (44.4)	15 (55.6)		5 (18.5)	22 (81.5)		15 (55.6)	12 (44.4)		27 (100.0)	0 (0.0)	
Distant metastasis																
No	175 (97.2)	102 (58.3)	73 (41.7)	0.65	55 (31.4)	120 (68.6)	0.6524	33 (18.9)	142 (81.1)	1	75 (42.9)	100 (57.1)	0.6537	172 (98.3)	3 (1.7)	
Yes	5 (2.8)	4 (80.0)	1 (20.0)		2 (40.0)	3 (60.0)		1 (20.0)	4 (80.0)		3 (60.0)	2 (40.0)		5 (100.0)	0 (0.0)	
Tumor stage																
I/II	145 (80.6)	85 (58.6)	60 (41.4)	1	44 (30.3)	101 (69.7)	0.4273	27 (18.6)	118 (81.4)	0.8136	58 (40.0)	87 (60.0)	0.0868	142 (97.9)	3 (2.1)	
III/IV	35 (19.4)	21 (60.0)	14 (40.0)		13 (37.1)	22 (62.9)		7 (20.0)	28 (80.0)		20 (57.1)	15 (42.9)		35 (100.0)	0 (0.0)	

Table II. Expression of cancer stem cell markers in different subtypes of breast cancer.

Breast cancer type	CD24 (%)			CD44 (%)			Oct3/4 (%)			Notch-4 (%)			ALDH1A1 (%)		
	Negative	Positive	P-value	Negative	Positive	P-value	Low	High	P-value	Low	High	P-value	Low	High	P-value
TNBC	11 (55.0)	9 (45.0)	0.3456	3 (15.0)	17 (85.0)	0.2964	3 (15.0)	17 (85.0)	0.9795	15 (75.0)	5 (25.0)	0.0013	19 (95.0)	1 (5.0)	0.4504
HER2 ⁺ (ER-/PR-)	6 (85.7)	1 (14.3)		3 (42.9)	4 (57.1)		1 (14.3)	6 (85.7)		5 (71.4)	2 (28.6)		7 (100.0)	0 (0.0)	
Luminal	92 (60.1)	61 (39.9)		43 (28.1)	110 (71.9)		25 (16.3)	128 (83.7)		56 (36.6)	97 (63.4)		151 (98.7)	2 (1.3)	

we examined the expression of the CSC markers CD24, CD44, Oct3/4, Notch-4 and ALDH1A1 in tumor tissues (n=180) and normal epithelial tissues (n=20) obtained from breast cancer patients. As shown in Fig. 1, expression of CD44, Oct3/4 and Notch-4, but not CD24 and ALDH1A1, was significantly induced in the tumor tissues compared to the normal epithelial tissues of breast cancer patients.

P2Y₂R expression is also significantly increased in tumor tissue and has a significant correlation only with Notch-4 of the cancer stem cell markers evaluated. In our previous study, we suggested that P2Y₂R has an important role in tumor progression and metastasis in highly metastatic breast cancer cells, such as MDA-MB-231 and RT-R breast cancer cells (16-19). In addition, Ko *et al* (19). showed that induced expression of CSC markers in RT-R-MDA-MB-231 cells. Therefore, in the present study, we examined whether expression of P2Y₂R and CSC markers is induced in breast cancer patients and, if so, whether there is a relationship between P2Y₂R and CSC markers in these patients. As depicted in Fig. 2A, we confirmed that P2Y₂R expression was increased in the tumor tissues of breast cancer patients compared to normal epithelial tissues. We also found that P2Y₂R expression had a significant correlation only with Notch-4 in breast cancer patients (Fig. 2B). Immunohistochemical staining results showed that Notch-4 and P2Y₂R were highly expressed in tumor tissues compared to normal tissues (Fig. 2C).

Discussion

Breast CSCs are characterized by high expression of CD44 and low expression of CD24 (CD44⁺/CD24^{-low}), and Notch-4, Oct3/4 and ALDH1 have also been suggested as CSC markers (20-24). The present study shows that of CSC markers, expression of CD44, Oct3/4 and Notch-4, but not CD24 and ALDH1A1, was significantly induced in tumor tissues compared to normal epithelial tissues obtained from breast cancer patients. Recent studies have suggested that ALDH1, a detoxifying enzyme responsible for the oxidation of retinol to retinoic acid, may be a potent marker of breast CSCs (24-27). However, there is controversy regarding the use of ALDH1 as a breast CSC marker. Resetskova *et al* (28). reported that ALDH1-positive cells did not significantly increase following neoadjuvant chemotherapy in surgical specimens, whereas other researchers (25-27), including Tanei *et al* (24), reported that ALDH1 was a more significant predictive marker than CD44⁺/CD24⁻ for the identification of breast CSCs with respect to resistance to chemotherapy. In our previous *in vitro* study (19), ALDH1 levels were significantly increased in RT-R-MDA-MB-231 cells, indicating an increased number of CSCs, compared to MDA-MB-231 cells; furthermore, ALDH1 was not expressed in MCF-7 and T47D cells, even in RT-R-MCF-7 and RT-R-T47D cells, suggesting that ALDH1 may be a potent marker for breast CSCs and that ALDH1-positive breast CSCs may play an important role in radioresistance. ALDH1 has three main isotypes, ALDH1A1, ALDH1A2, and ALDH1A3 (28). Recent reports suggest that ALDH1, and its isotype ALDH1A1 in particular, are useful CSC markers that may be used to enrich tumor-initiating subpopulations from various cell lines and primary tumors




Figure 1. CD44, Oct3/4 and Notch-4 cancer stem cell markers are significantly expressed in the tumor tissues compared with normal epithelial tissues of patients with breast cancer. The expression levels of cancer stem cell markers (CD24, CD44, Oct3/4, Notch-4 and ALDH1A1) were compared in normal epithelial tissues (n=20) and tumor tissues (n=180) of patients with breast cancer (n=180). ALDH, aldehyde dehydrogenase.

and that they are associated with cancer progression (29-31). Therefore, among the isotypes of ALDH1, we investigated expression of ALDH1A1 in tumor tissues of human breast cancer patients. However, among our 180 breast cancer patients, expression of ALDH1A1 was not induced in tumor tissues compared to normal epithelial tissues. Thus, more work is needed to clarify this issue.

As mentioned above, P2Y₂R has, according to an *in vitro* study, an important role in tumor progression and metastasis. We also wondered whether P2Y₂R is highly expressed in the tumor tissues of breast cancer patients. As expected, P2Y₂R expression was significantly induced in tumor tissues compared to normal epithelial tissues. More interestingly, we found that P2Y₂R expression has a significant correlation with Notch-4 in breast cancer patients. Many studies have confirmed increased expression of the Notch receptor and its ligands in breast cancer tissue compared with normal breast tissue (32-34). The Notch receptor family comprises four transmembrane proteins. Rizzo *et al* (34) reported that Notch-1 and Notch-4 expression was low in normal breast tissue but that invasive ductal carcinoma and invasive lobular carcinoma exhibited 81 and 93% Notch-4 positivity, respectively. In particular, the role of Notch-4 in epithelial tumors was established by insertional mutagenesis in mice infected with mouse mammary tumor virus (35,36). Notch-4 is expressed in stem cells of the mammary gland terminal duct and is involved in the formation of branching structures that precede poorly differentiated adenocarcinoma and the incorporation of TAC-2 cells into duct branches. Notch-4 has also been implicated in growth factor β function, aggressive tumor phenotypes, and the transformation from normal mouse mammary epithelial cells to heterotypic cells (35-38). These results establish that the Notch-4 signaling pathway has an important role in regulating the growth and development of the mammary gland. Abnormal expression of Notch-4 may inhibit mammary stem cell differentiation, and Notch-4 gene

mutations may enhance mammary epithelial cell proliferation, thus leading to the occurrence of breast cancer. According to Wang *et al* (39), Notch-4 expression was significantly higher in patients with TNBC and HER-2-overexpressing breast cancer than in those with luminal breast cancer. They also suggested that Notch-4 expression is associated with aggressive clinicopathological and biological phenotypes and may predict poor prognosis in luminal breast cancer patients. Nonetheless, in the present study, Notch-4 was not significantly associated with tumor size, lymph node involvement, or clinical TNM stage (Table I). Moreover, as shown in Table II, Notch-4 levels were increased in non-TNBC and luminal breast cancer types compared with TNBC (Table II). In survival analysis, Notch-4 expression did not show any significance in the breast cancer patients enrolled in this study (data not shown). Interestingly, Notch-4 expression was significantly associated with P2Y₂R expression in breast cancer cells, even though expression of P2Y₂R was also not associated with tumor size, lymph node involvement, clinical TNM stage, TNBC (Table SI) or the overall survival rate (P=0.245; data not shown). As this study was performed with specimens from breast cancer patients who underwent surgery with wide excision or mastectomy, the patients enrolled were in the early phase rather than in the late phase. This fact is a possible reason why no significant relationship between several CSC markers and survival rate or recurrence was found. Although Notch-4 does not appear to be associated with the presence of hormone receptors, tumor size, and clinical TNM stage in human breast cancer patients, it is very meaningful that Notch-4 showed a notable correlation with P2Y₂R, which has important roles in tumor progression and metastasis, as noted in a previous study. As we mentioned in the Introduction, in *in vitro* study and *in vivo* mice model, P2Y₂R was closely related with the tumor progression, metastasis and acquisition of tolerance to other anticancer therapies (16-19). Accordingly, we surmise that we might obtain more impressive results regarding the relationship between Notch-4




Figure 2. P2Y₂R, which is also significantly expressed in the tumor tissues of breast cancer patients, correlates only with Notch-4, of the cancer stem cell markers. (A) P2Y₂R expression is significantly increased in the tumor tissue (n=180) compared with normal epithelial tissue (n=20) of patients with breast cancer (n=180). (B) P2Y₂R expression has a significant correlation with Notch-4 cancer stem cell marker in patients with breast cancer. (C) Immunohistochemical staining of P2Y₂R and Notch-4 in tumor tissues and normal epithelial tissues of patients with breast cancer.

and P2Y₂R in the prognosis of breast cancer patients, including the survival rate, by studying the tumor tissues of breast cancer patients in a later phase.

The above limitation might also be applied to the fact that expression of other CSCs, namely, CD44 and Oct3/4, in tumor tissues displayed no significant correlation with P2Y₂R expression in breast cancer patients. As we stated above,

RT-R-MDA-MB-231 cells derived from the highly metastatic breast cancer cell line MDA-MB-231 exhibited increased expression of CSC markers, including CD44 and Oct3/4, with promotion of invasion and tumor growth through activation of P2Y₂R. Thus, it is also expected that expression of CD44 and Oct3/4 is related to P2Y₂R expression as well as Notch-4. Regardless, we found no significant relationship between CD44

or Oct3/4 and P2Y₂R. CD44 is a transmembrane receptor that is associated with cancer-initiating cell development and tumor metastasis (40-42). CD44 binds to hyaluronic acid (HA), resulting in effective activation of STAT-3 pathways, which play important roles in the regulation of the growth and maintenance of CSCs (43). In addition, STAT-3 activation has been associated with the resistance of tumor cells to chemotherapeutic agents and γ radiation (44,45). Oct3/4, also known as Oct3, Oct4 or Pit-Oct0Unc class 5 homeobox 1 (POU5F1), is a transcription factor (46), and overexpression of Oct3/4 has been shown to enhance the stemness of CSCs and to induce the pathogenesis of several human cancers (47-49). Based on these reports, it is possible to expect that data based on tumor tissues of breast cancer patients in a later phase may reveal a significant correlation between CD44 or Oct3/4 and P2Y₂R.

Taken together, there is no report to date on the correlation between Notch-4 and P2Y₂R in tumor progression or tumorigenesis. Thus, it might be valuable to investigate how P2Y₂R correlates with Notch-4, and further study may uncover a novel strategy for developing targeted therapy.

Acknowledgements

Not applicable.

Funding

The present study was supported by The Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (grant no. 2018R1A2B6001786).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

DCK performed the experiments, analyzed the data and drafted the initial manuscript. HJ performed the experiments, analyzed and interpreted the data. JSL collected patients' samples, performed experiments and analyzed the data. ES performed experiments and analyzed the data. GWL and HJK designed the study, interpreted the data and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. This retrospective study was approved by the Institutional Review Board of Gyeongsang National University Hospital with a waiver of informed consent (GNUH-2018-05-010).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. *CA Cancer J Clin* 65: 87-108, 2015.
2. Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. *Nat Med* 12: 895-904, 2006.
3. Steeg PS: Cancer: Micromanagement of metastasis. *Nature* 449: 671-673, 2007.
4. Eccles SA and Welch DR: Metastasis: Recent discoveries and novel treatment strategies. *Lancet* 369: 1742-1757, 2007.
5. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. *Cancer Res* 66: 9339-9344, 2006.
6. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, *et al*: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci USA* 106: 16281-16286, 2009.
7. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JJ, *et al*: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. *Proc Natl Acad Sci USA* 106: 13820-13825, 2009.
8. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, *et al*: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. *J Natl Cancer Inst* 100: 672-679, 2008.
9. Phillips TM, McBride WH and Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. *J Natl Cancer Inst* 98: 1777-1785, 2006.
10. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athellogou M and Brauch H: Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. *Clin Cancer Res* 11: 1154-1159, 2005.
11. White N, Butler PE and Burnstock G: Human melanomas express functional P2X(7) receptors. *Cell Tissue Res* 321: 411-418, 2005.
12. Schafer R, Sedehizade F, Welte T and Reiser G: ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. *Am J Physiol Lung Cell Mol Physiol* 285: L376-L385, 2003.
13. Shabbir M, Ryten M, Thompson C, Mikhailidis D and Burnstock G: Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. *BJU Int* 101: 106-112, 2008.
14. Janssens R and Boeynaems JM: Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. *Br J Pharmacol* 132: 536-546, 2001.
15. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V and Di Virgilio F: Increased level of extracellular ATP at tumor sites: In vivo imaging with plasma membrane luciferase. *PLoS One* 3: e2599, 2008.
16. Jin H, Eun SY, Lee JS, Park SW, Lee JH, Chang KC and Kim HJ: P2Y₂ receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells. *Breast Cancer Res* 16: R77, 2014.
17. Joo YN, Jin H, Eun SY, Park SW, Chang KC and Kim HJ: P2Y₂R activation by nucleotides released from the highly metastatic breast cancer cell MDA-MB-231 contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment. *Oncotarget* 5: 9322-9334, 2014.
18. Jin H, Ko YS and Kim HJ: P2Y₂R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer. *Int J Oncol* 53: 1953-1966, 2018.
19. Ko YS, Jin H, Lee JS, Park SW, Chang KC, Kang KM, Jeong BK and Kim HJ: Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells. *Oncol Rep* 40: 3752-3762, 2018.
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA* 100: 3983-3988, 2003.

21. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG: Isolation and in propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. *Cancer Res* 65: 5506-5511, 2005.
22. Koo BS, Lee SH, Kim JM, Huang S, Kim SH, Rho YS, Bae WJ, Kang HJ, Kim YS, Moon JH and Lim YC: Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. *Oncogene* 34: 2317-2324, 2015.
23. Tsai YH, VanDussen KL, Sawey ET, Wade AW, Kasper C, Rakshit S, Bhatt RG, Stoeck A, Maillard I, Crawford HC, *et al*: ADAM10 regulates Notch function in intestinal stem cells of mice. *Gastroenterology* 147: 822-834.e13, 2014.
24. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. *Clin Cancer Res* 15: 4234-4241, 2009.
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, *et al*: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 1: 555-567, 2007.
26. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N and Noguchi S: Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. *Cancer Sci* 100: 1062-1068, 2009.
27. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, *et al*: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clin Cancer Res* 16: 45-55, 2010.
28. Resetskova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1 in breast cancer: A story of stem cells and tumor microenvironment. *Breast Cancer Res Treat* 123: 97-108, 2010.
29. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. *Cancer Res* 69: 3382-3389, 2009.
30. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, *et al*: Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. *PLoS One* 5: e10277, 2010.
31. Ciccone V, Terzuoli E, Donnini S, Giachetti A, Morbidelli L and Ziche M: Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1 α /VEGF signalling in MCF-7 breast cancer cells. *J Exp Clin Cancer Res* 37: 311, 2018.
32. Parr C, Watkins G and Jiang WG: The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. *Int J Mol Med* 14: 779-786, 2004.
33. Zardawi SJ, Zardawi I, McNeil CM, Millar EK, McLeod D, Morey AL, Crea P, Murphy NC, Pinese M, Lopez-Knowles E, *et al*: High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. *Histopathology* 56: 286-296, 2010.
34. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, *et al*: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. *Cancer Res* 68: 5226-5235, 2008.
35. Gallahan D and Callahan R: Mammary tumorigenesis in feral mice: Identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. *J Virol* 61: 66-74, 1987.
36. Smith GH, Gallahan D, Diella F, Jhappan C, Merlino G and Callahan R: Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. *Cell Growth Differ* 6: 563-577, 1995.
37. Uyttendaele H, Soriano JV, Montesano R and Kitajewski J: Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. *Dev Biol* 196: 204-217, 1998.
38. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, *et al*: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. *Nat Med* 8: 979-986, 2002.
39. Wang JW, Wei XL, Dou XW, Huang WH, Du CW and Zhang GJ: The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. *Oncol Lett* 15: 8749-8755, 2018.
40. Marhaba R and Zöller M: CD44 in cancer progression: Adhesion, migration and growth regulation. *J Mol Histol* 35: 211-231, 2004.
41. Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. *Eur J Cancer* 46: 1271-1277, 2010.
42. Zöller M: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? *Nat Rev Cancer* 11: 254-267, 2011.
43. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, *et al*: The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁺ stem cell-like breast cancer cells in human tumors. *J Clin Invest* 121: 2723-2735, 2011.
44. Tan Q, Wang H, Hu Y, Hu M, Li X, Aodengqimuge, Ma Y, Wei C and Song L: Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy. *Cancer Sci* 106: 1023-1032, 2015.
45. Bonner JA, Trummell HQ, Willey CD, Plants BA and Raisch KP: Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. *Radiother Oncol* 92: 339-344, 2009.
46. Ling GQ, Chen DB, Wang BQ and Zhang LS: Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines. *Oncol Lett* 4: 1264-1268, 2012.
47. Du Z, Jia D, Liu S, Wang F, Li G, Zhang Y, Cao X, Ling EA and Hao A: Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. *Glia* 57: 724-733, 2009.
48. Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, Sawada T, Ohira M and Hirakawa K: Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. *J Surg Res* 174: 130-135, 2012.
49. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. *Carcinogenesis* 26: 495-502, 2005.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.